Back to search results

Understanding Prostate Cancer in Native American Populations

This study, called NAT-Geno, aims to understand how genes in prostate cancer (PC) affect Native American men. Researchers will analyze existing tumor tissue samples and collect blood samples to learn more about how your cancer might progress and respond to treatment. You may be eligible if you are a man aged 18 to 100, self-identify as Native American, and have a confirmed diagnosis of prostate cancer. The main goal is to compare the genetic makeup of prostate cancer over 1 to 3 years. The current recruitment status is unclear.

Study design
This is an observational study planning to enroll 150 participants. It will involve analyzing existing tissue samples and new blood samples.
What's involved
You would provide written informed consent. Tissue samples will be taken from existing archived collections, and blood samples will be collected within the first year of enrollment.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, measuring differences in genomic profiles, will be assessed at 1-3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06960798

Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno)

Recruiting
Not specifiedAges 18+Observational
University of Oklahoma
~150 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:Bio-specimen CollectionBlood Draw

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Difference in the genomic profiles of Prostate Cancer
Measured over 1-3 years

Conditions

Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
Oklahoma1

Study leadership

  • Adanma Ayanambakkam, MD · PRINCIPAL_INVESTIGATOR · University of Oklahoma

Who to contact

Lead Onco Nurse
[email protected]
405-271-8777
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written informed consent signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses.
At least 18 years-of-age at the time of signature of the informed consent form (ICF).
Patients who self-identify as Native American.
Patients with a pathologically proven diagnosis of PC (any stage).
Availability of most recent archived tumor samples.

Exclusion

Patients not of Native American descent or identity.
Patient does not have archival tissue available.

What this trial measures

  • Difference in the genomic profiles of Prostate Cancer1-3 years

    Comprehensively characterize the genomic profile of prostate cancer in Native American patients compared to Caucasian patients. Genetic testing will be conducted using Caris Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS).